New eye drug faricimab tested for blinding disease
NCT ID NCT07581782
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test the drug faricimab, given as eye injections, in 50 people with wet age-related macular degeneration (nAMD). The goal is to see if it improves vision and eye health. Participants will receive 4 initial doses, then more as needed. The study is observational, meaning there is no comparison group, and it has not yet started recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- faricimab (eye injection)
- What this could lead to
- If successful, this could show that faricimab helps stabilize or improve vision in people with wet age-related macular degeneration.
- What could go wrong
- This is a small, early observational study with no comparison group. Results may not apply to all patients, and faricimab may not work as well in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene therapy tame wet AMD for years?
- Laser zap before eye injection could cut needle count for wet AMD
- New eye injection shows promise for wet AMD in everyday practice
- New syringe could simplify High-Dose eye treatment
- New eye drug trial aims for safer wet AMD treatment
- Gene therapy for wet AMD: 4-Year safety check begins